Cambrian Bio is a clinical-stage drug development company focused on creating innovative therapeutics aimed at treating and preventing chronic diseases associated with aging. The company collaborates with leading scientists to explore the biological mechanisms that change with age, allowing them to develop a new class of medicines. Their approach involves targeting specific biological drivers of aging, with the goal of not only treating existing conditions but also enhancing overall healthspan. Cambrian Bio operates as a Distributed Development Company (DisCo), which enables them to advance multiple scientific inventions simultaneously, fostering partnerships across the innovation ecosystem.

The company's pipeline includes a diverse range of therapeutics, such as ATX-304, a small molecule designed to activate AMPK and mitochondrial functions for treating cardiometabolic diseases. Other notable projects include Tornado Therapeutics, which is developing safer mTOR inhibitors for cancer and autoimmune diseases, and Oviva Therapeutics, focused on extending ovarian function to improve women's health. Cambrian Bio's multifaceted approach aims to address various age-related conditions by restoring cellular function, enhancing tissue regeneration, and mitigating chronic inflammation, ultimately striving to redefine healthcare in the 21st century.

United States

Cambrian Bio is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

Cancer

Cardiovascular Diseases

Immune System Diseases

Pathological Conditions

Cambrian Bio

Cardiometabolic Disease

ATX-304

Biologics

CAM-9782

Small Molecule Pharmaceuticals

Autoimmune disease

CAM-5746

Rare diseases

CAM-5747

VTA-300

VTA-100

CAM-5131

CAM-5132

CAM-1108

Cardiovascular disease

CAM-6019

Fibrotic Diseases

CAM-4628

CAM-7276

New York

Therapeutic

Cambrian Bio

Company Details